Exploring Abeta42 Monomer Diffusive Dynamics on Fibril Surfaces through Molecular Simulations

Author:

Ma Yuan-Wei,Wang Guan-Fang,Tsai Min-YehORCID

Abstract

AbstractAlzheimer’s disease is closely linked to the aggregation of Abeta42 peptides, which follow a complex pathway involving primary nucleation and secondary processes. While previous research has underscored the importance of secondary processes, this study employs molecular dynamics simulations to delve into their molecular-level intricacies. We employ coarse-grained molecular dynamics with a freely diffusing Abeta42 monomer alongside a pre-formed fibril structure. We conducted comprehensive calculations of the monomer’s diffusion coefficient (D) on the fibril surface, considering both straight and twisted fibril structures, as well as various monomer surface orientations. Notably, our findings reveal a robust correlation between the monomer’s diffusion coefficient (D) and its surface orientation, irrespective of the degree of fibrillar twisting. Additional analysis of monomer orientation further reinforces the orientation-dependent diffusion results, distinguishing between parallel and perpendicular alignments. Additionally, we explore how distinct fibril surfaces influence monomer dynamics. We compared the C-terminal and N-terminal surfaces and found that the monomer exhibits lower diffusion coefficients (D) on the N-terminal surface. Surface roughness, quantified using root-mean-square deviation (RMSD), revealed significant differences between these surfaces. The dissimilarity in shape and roughness contributes to the observed differences in monomer dynamics, highlighting the role of surface characteristics in molecular-level aggregation.

Publisher

Cold Spring Harbor Laboratory

Reference70 articles.

1. The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics

2. Failure to Demonstrate Efficacy of Aducanumab: An Analysis of the EMERGE and ENGAGE Trials as Reported by Biogen, December 2019;Alzheimers. Dement,2021

3. Center for Drug Evaluation; Research. FDA’s decision to approve new treatment for Alzheimer’s disease. U.S. Food and Drug Administration. https://www.fda.gov/drugs/news-events-human-drugs/fdas-decision-approve-new-treatment-alzheimers-disease (accessed 2023-12-23).

4. Piller, C. Second death linked to potential antibody treatment for Alzheimer’s disease. Science News. https://www.science.org/content/article/second-death-linked-potential-antibody-treatment-alzheimer-s-disease?utm_source=sfmc&utm_medium=email&utm_campaign=DailyLatestNews&utm_content=alert&et_rid=504035807&et_cid=4509061.

5. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3